In Reply to USPTO Correspondence of March 25, 2008

Attorney Docket No. 3824-061668

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application.

Claims 1-35 (Cancelled).

Claim 36 (Currently Amended): A compound represented by general formula (I):

(1S,3R,4S,6R,7S,8R,10R)-1-hydroxy-3-methyloxy-3,10-epoxy-8-isobutyryloxygermacra-11(13)-en-6,12-olide

wherein R₁ represents hydroxyl and R₂ represents methoxy.

Application No. 10/580,588
Paper Dated: August 25, 2008
In Reply to USPTO Correspondence of March 25, 2008
Attorney Docket No. 3824-061668

Claim 37 (Currently Amended): A compound represented by general formula (II):

 $\underline{(1S,3R,6R,7R,8R,10R)-1-hydroxy-3-methoxy-3,10-epoxy-8-isobutyryloxygermacra-4,11(13)-dien-6,12-olide}$

$$R_3$$
 CH_3 O CH_3 CH_3 CH_3 CH_3 CH_3 CH_2 CH_3 CH_3 CH_2 CH_3 CH_3

wherein R₃ represents hydroxyl and R₄ represents methoxy.

Claim 38 (Currently Amended): A compound represented by general formula (III):

(4S,5R)-4-hydroxy-4-((1E,3S)-3-hydroxy-1-buteneyl]-3,3,5-trimethyl cyclohexanone

Application No. 10/580,588
Paper Dated: August 25, 2008
In Reply to USPTO Correspondence of March 25, 2008
Attorney Docket No. 3824-061668

(III)

wherein 3-hydroxyl in 3-hydroxy-1-butenyl is in a 3S configuration.

Claim 39 (Previously Presented): A carcinostatic agent, comprising as an active ingredient a compound according to claim 36.

Claim 40 (Previously Presented): The carcinostatic agent according to claim 39, for use in the treatment of animal or human cancer.

Claim 41 (Previously Presented): The carcinostatic agent according to claim 40, wherein said cancer is leukemia.

Claim 42 (Previously Presented): The carcinostatic agent according to claim 41, wherein said leukemia is acute myelogenous leukemia.

Claim 43 (Previously Presented): An anti-acute myelogenous leukemia agent, comprising as an active ingredient at least one compound selected from the group consisting of a compound represented by formula (I), wherein R_1 and R_2 represent hydroxyl, a compound represented by formula (I), wherein R_1 represents a hydrogen atom and R_2 represents hydroxyl, a compound represented by formula (I), wherein R_1 represents a hydrogen atom and R_2 represents methoxy,

a compound represented by formula (II), wherein R₃ and R₄ represent methoxy, a compound represented by formula (II), wherein R₃ represents methoxy and R₄ represents hydroxyl,

a compound represented by general formula (IV),

In Reply to USPTO Correspondence of March 25, 2008

Attorney Docket No. 3824-061668

$$OH_3$$
 OH_3 OH_2 OH_3 OH_3 OH_3 OH_3 OH_3 OH_3 OH_4 OH_3 OH_5 OH_5

, and

a compound represented by general formula (V),

$$CH_3$$
 CH_3
 CH_3
 CH_3
 CH_3
 CH_3
 CH_3
 CH_3
 CH_3
 CH_2
 CH_3
 CH_3

Claim 44 (Previously Presented): The anti-acute myelogenous leukemia agent according to claim 43, for use in the treatment of animal or human acute myeloid leukemia.

Claim 45 (Previously Presented): A process for producing a composition comprising the steps of:

providing a raw material comprising the compounds of claims 36 to 38 and 43; extracting said raw material with a solvent;

supplying said extract to an ion-exchange chromatograph wherein said extract is subjected to solvent extraction with a first lower alcohol, a second lower alcohol, and optionally a lower ester in that order,

whereby a composition comprising each of said compounds is provided in a fraction of said second lower alcohol.

O57592.DOC

Claim 46 (Previously Presented): The process according to claim 45, wherein said raw material is a plant belonging to the family Compositae or a plant belonging to the genus Ludwigia of the family Onagraceae.

Claim 47 (Previously Presented): A process for obtaining compounds comprising the steps of:

providing a composition comprising the compounds of claims 36 to 38 and 43; and

repeating the separation of said composition by chromatography a plurality of times to obtain said compounds.

Claim 48 (Previously Presented): The process according to claim 47, wherein said composition has been produced by the process according to claim 45.

Claim 49 (Previously Presented): A process for separating a composition containing compounds according to claims 36 to 38 and 43 into a first composition and a second composition, said process comprising:

providing a composition comprising said compounds; and

separating said composition by normal phase chromatography and then by reverse phase chromatography into a first composition and a second composition,

said first composition comprising compounds according to claims 36 to 38, a compound represented by general formula (I), wherein R₁ and R₂ represent hydroxyl, a compound represented by general formula (IV), and a compound represented by general formula (V),

said second composition comprising a compound represented by general formula (I), wherein R_1 represents a hydrogen atom and R_2 represents hydroxyl and a compound represented by general formula (I), wherein R_1 represents a hydrogen atom and R_2 represents methoxy.

Claim 50 (Previously Presented): The process according to claim 49, wherein said composition has been produced by the process according to claim 45.

In Reply to USPTO Correspondence of March 25, 2008

Attorney Docket No. 3824-061668

Claim 51 (Previously Presented): A process for producing compounds comprising the steps of:

providing a composition comprising the compounds of claims 36 to 38, a compound represented by general formula (I), wherein R_1 and R_2 represent hydroxyl, a compound represented by general formula (IV), and a compound represented by general formula (V); and

separating said composition by at least one of normal phase chromatography, reverse phase chromatography, liquid chromatography, or a combination thereof to isolate said compounds.

Claim 52 (Previously Presented): The process according to claim 51, wherein said composition is a first composition produced by the process according to claim 49.

Claim 53 (Previously Presented): A process for producing compounds comprising the steps of:

providing a composition comprising compounds represented by general formula (I), wherein R_1 represents a hydrogen atom and R_2 represents hydroxyl and a

compound represented by general formula (I), wherein R_1 represents a hydrogen atom and R_2 represents methoxy; and

separating said composition by at least one of normal phase chromatography, reverse phase chromatography, or a combination thereof to isolate said compounds.

Claim 54 (Previously Presented): The process according to claim 53, wherein said composition is a second composition produced by a process according to claim 49.

Claim 55 (Previously Presented): A compound according to claim 36, wherein said compound is produced by a process according to claim 47.

Claim 56 (Previously Presented): An anti-ovarian cancer agent, comprising as an active ingredient a compound represented by general formula (II), wherein R₃ and R₄ represent methoxy.

In Reply to USPTO Correspondence of March 25, 2008

Attorney Docket No. 3824-061668

Claim 57 (Previously Presented): The anti-ovarian cancer agent according to claim 56 for use in the treatment of an animal or human ovarian cancer.

Claim 58 (Previously Presented): An anti-prostatic cancer agent, comprising as an active ingredient a compound represented by general formula (Π), wherein R_3 and R_4 represent methoxy.

Claim 59 (Previously Presented): The anti-prostatic cancer agent according to claim 56, for use in the treatment of an animal or human prostatic cancer.

Claim 60 (Previously Presented): A process for producing a composition comprising

a compound represented by general formula (VI):

$$CH_3$$
 CH_3
 CH_3
 CH_3
 CH_3
 CH_3
 CH_3
 CH_3
 CH_3
 CH_2
 CH_2
 CH_2

a compound represented by general formula (VII):

In Reply to USPTO Correspondence of March 25, 2008

Attorney Docket No. 3824-061668

(VII)

a compound represented by general formula (VIII):

(VIII)

, and

a compound represented by general formula (IX):

In Reply to USPTO Correspondence of March 25, 2008

Attorney Docket No. 3824-061668

said process comprising the steps of: providing a raw material comprising said compounds; extracting said raw material with a solvent; and

supplying said extract to an ion-exchange chromatograph wherein said extract is subjected to solvent extraction with a first lower alcohol, a second lower alcohol, and optionally a lower ester in that order,

whereby a composition comprising said compounds is provided in a fraction of said second lower alcohol.

Claim 61 (Previously Presented): The process according to claim 60, wherein said raw material is a plant belonging to the family Compositae or a plant belonging to the genus Ludwigia of the family Onagraceae.

Claim 62 (Previously Presented): A process for obtaining compounds represented by general formulae (VI) to (IX), comprising the steps of:

providing a composition comprising said compounds; and

repeating the separation of said composition by chromatography a plurality of times to obtain said compounds.

Claim 63 (Previously Presented): The process according to claim 62, wherein said composition has been produced by the process according to claim 60.

Claim 64 (Previously Presented): A process for separating a composition comprising compounds represented by general formulae (VI) to (IX) into a third composition and a fourth composition, said process comprising the steps of:

providing a composition comprising said compounds; and

separating said composition by normal phase chromatography and then by reverse phase chromatography into a third composition and a fourth composition,

said third composition comprising a compound represented by general formula (VI) and a compound represented by general formula (IX),

said fourth composition comprising a compound represented by general formula (VII) and a compound represented by general formula (VIII).

Attorney Docket No. 3824-061668

Claim 65 (Previously Presented): The process according to claim 64, wherein said composition has been produced by the process according to claim 60.

Claim 66 (Previously Presented): A process for producing a compound represented by general formula (VI) and a compound represented by general formula (IX), said process comprising the steps of:

providing a composition comprising said compounds; and

separating said composition by at least one of normal phase chromatography, reverse phase chromatography, liquid chromatography, or a combination thereof to isolate said compounds.

Claim 67 (Previously Presented): The process according to claim 66, wherein said composition is a third composition produced by the process according to claim 64.

Claim 68 (Previously Presented): A process for producing a compound represented by general formula (VII) and a compound represented by general formula (VIII), said process comprising the steps of:

providing a composition comprising said compounds; and

separating said composition by at least one of normal phase chromatography, reverse phase chromatography, liquid chromatography, or a combination thereof to isolate said compounds.

Claim 69 (Previously Presented): The process according to claim 68, wherein said composition is a fourth composition produced by a process according to claim 64.

Claim 70 (Previously Presented): Compounds represented by general formulae (VI) to (IX), produced by a process according to claim 62.